dyspepsia
DYSPEPSIA

Dyspepsia is having any one of the following: Disturbing postprandial fullness, early satiation, epigastric pain and/or burning felt predominantly in the upper abdomen.

It is considered a symptom complex rather than a specific diagnosis.

Acid suppression is the recommended initial therapy.

Dyspepsia Drug Information

Drug Information
Belcid
aluminium hydroxide + magnesium hydroxide + simeth...

Indication: Antacid, antiflatulent & demulcent in gastric hyperacidity & heartburn. Symptomatic relief of peptic &...

Belcid Forte
aluminium hydroxide + magnesium hydroxide + simeti...

Indication: Symptomatic relief of hyperacidity associated w/ PUD, gastritis, peptic esophagitis, gastric hyperacidity, hea...

Indication: Peptic ulcer associated w/ H pylori.

Indication: Reflux disease & associated symptoms. Prevention of gastroduodenal ulcers induced by NSAIDs in patients at...

Indication: 20 mg: Mild GERD & associated symptoms eg, heartburn, acid regurgitation, pain on swallowing. Long-term ma...

Indication: Healing of erosive esophagitis (EE). Maintenance of healed EE & relief of heartburn. Heartburn associated ...

Eno
citric acid + sodium bicarbonate + sodium carbonat...

Indication: Relief of indigestion & stomach gas.

Indication: Relief of flatulence; gas expulsion for gastroscopic & radiographic exam.

Gaviscon/Gaviscon Double Action
calcium carbonate + sodium alginate + sodium bicar...

Indication: Relief from pain & discomfort of heartburn & acid indigestion.

Indication: Adjunctive therapy in treatment of peptic ulcer, irritable bowel syndrome & acute enterocolitis.

2  /  11
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 25 Nov 2020
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.